According to the Australian Institute of Health and Welfare, there are more than 1.7 million Australians that live with the biomedical signs of chronic kidney disease. While not all will deteriorate to kidney failure, it leads to the 22,000 deaths annually which could be reduced from earlier detection and better management, an initiative launched by
Read More
12% of global health expenditure is spent on diabetes. That equates to approximately USD $673 billion. Scarily, 1 in 2 adults with diabetes is undiagnosed. Diabetic kidney disease (DKD) is directly caused by diabetes, and the damage the disease does to the kidneys. It is estimated that 1 in 3 diabetics will go on to
Read More
We are all different. It’s what makes us unique. Companies are all too aware of this, with experiences and products evolving to cater to personal needs and preferences. From mixing custom skin care formulations to Spotify music recommendations, personalised experiences are more memorable and valuable to the customer. The same goes for medicine. Personalisation means
Read More
Australian medtech developer Proteomics International Laboratories (PILL, ASX: PIQ) has reached a landmark milestone having secured CE Mark certification for commericalisation of their in vitro diagnostic medical device in Europe, which can predict the early onset of diabetic kidney disease. The device, PromarkerD, takes a blood test which then creates a unique protein fingerprint which
Read More